Cambrian Bio

Developer of a portfolio of medicines designed to target the causes of age-related diseases. The company develops therapies and medicines to create interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life, enabling scientists to transmit their discoveries from the lab into the clinic and bring medicines to patients in need.

2 past transactions

Vita Therapeutics

Series A in 2021
Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients.

Sensei Biotherapeutics

Series A in 2020
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of medicines that alter the treatment landscape and contributing value to patients and society. Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.